Early response to upfront neoadjuvant chemotherapy (CAPOX) alone in low- and intermediate-risk rectal cancer: a single-arm phase II trial

Author:

Deng Xiangbing1,Wu Qingbin1ORCID,Bi Liang12,Yu Yongyang1,Huang Shuo1,He Du3,Wu Bing4,Gou Hongfeng5,Meng Wenjian1ORCID,Qiu Meng5,He Yazhou6ORCID,Wang Ziqiang1ORCID

Affiliation:

1. Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu, China

2. Department of Colorectal Surgery, Gansu Provincial Hospital, Lanzhou, China

3. Department of Pathology, West China Hospital, Sichuan University, Chengdu, China

4. Department of Radiology, West China Hospital, Sichuan University, Chengdu, China

5. Department of Abdominal Cancer, West China Hospital, Sichuan University, Chengdu, China

6. Department of Oncology, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, China

Abstract

Abstract Background With local recurrence of rectal cancer continuing to decrease, distant recurrence is becoming a major concern, especially for patients with low- and intermediate-risk stage II/III rectal cancer. Therefore, a new treatment strategy is warranted for these patients. This single-arm phase II trial aimed to assess the effect of neoadjuvant chemotherapy (NCT) in low- and intermediate-risk stage II/III rectal cancer and explore candidate radiological and clinical parameters for early prediction of tumour response after two cycles of CAPOX. Methods Patients with mid–low stage II/III rectal cancer with low and intermediate risk were examined. The primary outcome was defined as a clinicopathological response by integrating tumour longitudinal length reduction (TLLR) on MRI into pathological tumour regression grade (TRG). After completing NCT, patients with TRG0–2 and TRG3 with a TLLR rate greater than 30 per cent were considered to be responders. Secondary outcomes included pathological complete response (pCR), adverse events and local and distant recurrence. Results This study enrolled 61 eligible patients. No patient was converted to neoadjuvant chemoradiotherapy owing to tumour progression. The clinicopathological response and pCR rates were 78.7 and 21.3 per cent respectively. After two cycles of CAPOX, TLLR, TRG on MRI, and mucosal lesion regression grade on endoscopy had potential discriminative ability (area under the curve greater than 0.7) for predicting both clinicopathological and pathological response. Conclusion NCT alone achieves good tumour response rates in patients with low- and intermediate-risk stage II/III rectal cancer, and predicting tumour response to NCT is feasible at an early treatment phase. Registration number NCT03666442 (http://www.clinicaltrials.gov).

Funder

Ministry of Science and Technology of the People’s Republic of China

Department of Science and Technology of Sichuan Province

West China Hospital

Sichuan University

Clinical Research Incubation Project

West China Hospital, Sichuan University

Publisher

Oxford University Press (OUP)

Subject

Surgery

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3